Literature DB >> 12014812

Antisocial personality disorder and TC treatment outcomes.

Nena P Messina1, Eric D Wish, Jeffrey A Hoffman, Susanna Nemes.   

Abstract

There is a belief that persons diagnosed with antisocial personality disorder (APD) do not respond well to treatment, but the existing research has not supported this hypothesis. This study examined the relationship of APD to therapeutic community (TC) treatment outcomes. A total of 275 men and women were randomly assigned to two TCs. It was hypothesized that clients diagnosed with APD via the Millon Clinical Multiaxial Inventory (MCMI-II) would have poorer treatment outcomes than those with no APD. The MCMI-II was used to diagnose APD because of its focus in underlying pathological personality traits, as opposed to strict behavioral criteria as used in the Diagnostic and Statistical Manual of Mental Disorders classifications for APD; this hypothesis was not supported. Logistic regression analyses indicated that an MCMI-II diagnosis of APD was unrelated to treatment outcomes. Treatment completion was the most important factor in reducing recent drug use and post-discharge arrests. The results indicate that persons diagnosed with APD, with histories of substantial drug abuse and criminality, can benefit from TC treatment with aftercare in the community or at the very least, do as well as those with no APD. In light of the high prevalence rates of APD in substance-abusing populations, future research should continue to explore the many issues surrounding the diagnosis of APD, as well as its relationship to treatment outcomes.

Entities:  

Mesh:

Year:  2002        PMID: 12014812     DOI: 10.1081/ada-120002970

Source DB:  PubMed          Journal:  Am J Drug Alcohol Abuse        ISSN: 0095-2990            Impact factor:   3.829


  9 in total

1.  The severity of psychiatric disorders.

Authors:  Mark Zimmerman; Theresa A Morgan; Kasey Stanton
Journal:  World Psychiatry       Date:  2018-10       Impact factor: 49.548

2.  Antisocial behavioral syndromes and DSM-IV drug use disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions.

Authors:  Risë B Goldstein; Wilson M Compton; Attila J Pulay; W June Ruan; Roger P Pickering; Frederick S Stinson; Bridget F Grant
Journal:  Drug Alcohol Depend       Date:  2007-04-12       Impact factor: 4.492

Review 3.  Psychological interventions for antisocial personality disorder.

Authors:  Simon Gibbon; Conor Duggan; Jutta Stoffers; Nick Huband; Birgit A Völlm; Michael Ferriter; Klaus Lieb
Journal:  Cochrane Database Syst Rev       Date:  2010-06-16

4.  Personality disorders and retention in a therapeutic community for substance dependence.

Authors:  Douglas B Samuel; Donna M LaPaglia; Lisa M Maccarelli; Brent A Moore; Samuel A Ball
Journal:  Am J Addict       Date:  2011-10-04

5.  The 'antisocial' person: an insight in to biology, classification and current evidence on treatment.

Authors:  Chaturaka Rodrigo; Senaka Rajapakse; Gamini Jayananda
Journal:  Ann Gen Psychiatry       Date:  2010-07-06       Impact factor: 3.455

6.  Psychopathology in methamphetamine-dependent adults 3 years after treatment.

Authors:  Suzette Glasner-Edwards; Larissa J Mooney; Patricia Marinelli-Casey; Maureen Hillhouse; Alfonso Ang; Richard A Rawson
Journal:  Drug Alcohol Rev       Date:  2010-01

7.  Antisocial personality disorder predicts methamphetamine treatment outcomes in homeless, substance-dependent men who have sex with men.

Authors:  Jesse B Fletcher; Cathy J Reback
Journal:  J Subst Abuse Treat       Date:  2013-04-08

8.  Psychological interventions for antisocial personality disorder.

Authors:  Simon Gibbon; Najat R Khalifa; Natalie H-Y Cheung; Birgit A Völlm; Lucy McCarthy
Journal:  Cochrane Database Syst Rev       Date:  2020-09-03

9.  Associations between personality disorder characteristics and treatment outcomes in people with co-occurring alcohol misuse and depression.

Authors:  Kristen L McCarter; Sean A Halpin; Amanda L Baker; Frances J Kay-Lambkin; Terry J Lewin; Louise K Thornton; David J Kavanagh; Brian J Kelly
Journal:  BMC Psychiatry       Date:  2016-07-07       Impact factor: 3.630

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.